A double-blind, placebo-controlled comparative study and open-label extension study to confirm the efficacy and safety of E2020 in subjects with down syndrome having regression symptoms and disabled activities of daily living
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2018
Price : $35 *
At a glance
- Drugs Donepezil (Primary)
- Indications Down syndrome
- Focus Therapeutic Use
- Sponsors Eisai Co Ltd
- 21 Aug 2017 Status changed from active, no longer recruiting to completed.
- 10 Mar 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 26 Mar 2014 New trial record